Rachna Shroff

Rachna Shroff is a leading expert in biliary tract cancer and played a central role in the clinical development of FGFR2-targeted therapies for intrahepatic cholangiocarcinoma. Her research contributed to the pivotal FIGHT-202 trial that established pemigatinib as the first FDA-approved targeted therapy for FGFR2 fusion-positive cholangiocarcinoma. She has investigated the spectrum of FGFR2 alterations including fusions, mutations, and amplifications as therapeutic targets and characterized mechanisms of acquired resistance to FGFR inhibitors including secondary FGFR2 kinase domain mutations. Her translational and clinical work advances precision medicine approaches for molecularly profiled biliary tract cancers.